Back

What are the wider benefits of SGLT2 inhibitors for cardio-renal-metabolic conditions?

30 August 2025 (13:12 - 13:25)
Organised by: Logo
Congress Presentation Part of: Therapy in action: optimising heart failure care with SGLT2 inhibitors for outpatients Chronic Heart Failure Open Access ESC Congress 2025 European Society of Cardiology

About the speaker

Photo
Professor Nikolaus Marx

RWTH University Hospital Aachen, Aachen (Germany)

5 More presentations in this session

Presentation thumbnail
Welcome and introduction
Professor B. Bozkurt (Houston, US)
Slides
Presentation thumbnail
Why still talk about implementation of SGLT2 inhibitors?
Professor B. Bozkurt (Houston, US)
Presentation thumbnail
What are the barriers we need to break?
Professor P. Campbell (Newry, GB)
Presentation thumbnail
How do we identify patients with HFpEF?
Doctor C. Saldarriaga (Medellin, CO)
Presentation thumbnail
Close
Professor B. Bozkurt (Houston, US)

Access the full session

Session thumbnail
Therapy in action: optimising heart failure care with SGLT2 inhibitors for outpatients
Video

The Event

Event poster

ESC Congress 2025

30 August 2025 13:12 CET
You may be interested in
thumbnail
Congress Presentation
Cardiovascular benefits of SGLT2i in type 2 diabetes without heart failure: a subgroup analysis
30 August 2025
thumbnail
Congress Presentation
GLP1 receptor agonists, SGLT2 inhibitors, or both for cardio-renal protection?
30 August 2024
thumbnail
Congress Session
No time like the present: heart failure in the hospital setting
30 August 2024
thumbnail
Congress Presentation
Patient vascular model reveals anti-inflammatory effects of SGLT2 inhibitor by modulating endothelial-T cell crosstalk
31 August 2025

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources